The mechanisms of action of St. John’s wort: an update;Die Wirkmechanismen von Johanniskraut – Ein Update

Wiener Medizinische Wochenschrift

Volumn 165, Issue 11-12, 2015, Pages 229-235

  Schmidt, Mathias ^a   Butterweck, Veronika ^b  

^a Herbresearch Germany   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Active constituents; Hypericum perforatum; Pharmacology

Indexed keywords

GLUTAMIC ACID; HERBACEOUS AGENT; ION CHANNEL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; PLANT EXTRACT;

ADRENERGIC SYSTEM; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DEPRESSION; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; HYPERICUM PERFORATUM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; LOCOMOTION; NONHUMAN; OPEN FIELD TEST; TAIL SUSPENSION TEST; ANIMAL; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; HYPERICUM; METABOLISM; PHYTOTHERAPY; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION, PRECLINICAL; HYPERICUM; ION CHANNELS; NEUROTRANSMITTER AGENTS; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 84938956125     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-015-0372-7     Document Type: Article

References (39)

1. Anon. Community Herbal Monograph on Hypericum perforatum L. Herba (Well-established Medicinal Use). EMA/HMPC/101304/2008. London: European Medicines Agency; 2009.
2. Anon. Assessment Report on Hypericum perforatum L., Herba. EMA/HMPC/101303/2008. London: European Medicines Agency; 2009.
3. Bennett DA Jr., Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John’s wort (Hypericum). Ann Pharmacother. 1998;32(11):1201–8.
4. Nathan P. The experimental and clinical pharmacology of St John’s wort (Hypericum perforatum L.). Mol Psychiatry. 1999;4(4):333–8.
5. Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl). 2001;153(4):402–14.
6. Grundmann O, Lv Y, Kelber O, Butterweck V. Mechanism of St. John’s wort extract (STW3-VI) during chronic restraint stress is mediated by the interrelationship of the immune, oxidative defense, and neuroendocrine system. Neuropharmacology. 2010;58(4–5):767–73.
7. Butterweck V, Schmidt M. St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr. 2007;157(13–14):356–61.
8. Kiyan HT, Demirci B, Baser KH, Demirci F. The in vivo evaluation of anti-angiogenic effects of Hypericum essential oils using the chorioallantoic membrane assay. Pharm Biol. 2014;52(1):44–50.
9. Billard C, Merhi F, Bauvois B. Mechanistic insights into the antileukemic activity of hyperforin. Curr Cancer Drug Targets. 2013;13(1):1–10.
10. Zaher M, Tang R, Bombarda I, Merhi F, Bauvois B, Billard C. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa. Int J Oncol. 2012;40(1):269–76.
11. Novelli M, Beffy P, Menegazzi M, De Tata V, Martino L, Sgarbossa A, et al. St. John’s wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity. Acta Diabetol. 2014;51:113–121.
12. Zeng KW, Wang XM, Ko H, Kwon HC, Cha JW, Yang HO. Hyperoside protects primary rat cortical neurons from neurotoxicity induced by amyloid beta-protein via the PI3K/Akt/Bad/Bcl(XL)-regulated mitochondrial apoptotic pathway. Eur J Pharmacol. 2011;672(1–3):45–55.
13. Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al. Reduced Alzheimer’s disease pathology by St. John’s wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr Alzheimer Res. 2013;10(10):1057–69.
14. Kraus B, Wolff H, Heilmann J, Elstner EF. Influence of Hypericum perforatum extract and its single compounds on amyloid-beta mediated toxicity in microglial cells. Life Sci. 2007;81(11):884–94.
15. Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of Hypericum perforatum L. J Ethnopharmacol. 2010;131(3):511–21.
16. Xiuying P, Jianping L, Ruofeng S, Liye Z, Xuehong W, Yan L. Therapeutic efficacy of Hypericum perforatum L. extract for mice infected with an influenza A virus. Can J Physiol Pharmacol. 2012;90(2):123–30.
17. Esposito F, Sanna C, Del Vecchio C, Cannas V, Venditti A, Corona A, et al. Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities. Pathog Dis. 2013;68(3):116–24.
18. Huang N, Singh N, Yoon K, Loiacono CM, Kohut ML, Birt DF. The immuno-regulatory impact of orally-administered Hypericum perforatum extract on Balb/C mice inoculated with H1n1 influenza A virus. PLoS One. 2013;8(9):e76491.
19. De Marchis GM, Bürgi S, Kientsch U, Honegger UE. Vitamin E reduces antidepressant-related beta-adrenoceptor down-regulation in cultured cells. Comparable effects on St. John’s wort and tricyclic antidepressant treatment. Planta Med. 2006;72(15):1436–7.
20. Prenner L, Sieben A, Zeller K, Weiser D, Haberlein H. Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 2007;46(17):5106–13.
21. Jakobs D, Hage-Hülsmann A, Prenner L, Kolb C, Weiser D, Häberlein H. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John’s wort. J Pharm Pharmacol. 2013;65(6):907–15.
22. Chang Y, Wang SJ. Hypericin, the active component of St. John’s wort, inhibits glutamate release in the rat cerebrocortical synaptosomes via a mitogen-activated protein kinase-dependent pathway. Eur J Pharmacol. 2010;634(1–3):53–61.
23. Leuner K, Li W, Amaral MD, Rudolph S, Calfa G, Schuwald AM, et al. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca(2+) -permeable TRPC6 channels. Hippocampus. 2013;23(1):40–52.
24. Gibon J, Deloulme JC, Chevallier T, Ladeveze E, Abrous DN, Bouron A. The antidepressant hyperforin increases the phosphorylation of CREB and the expression of TrkB in a tissue-specific manner. Int J Neuropsychopharmacol. 2013;16(1):189–98.
25. Bouron A, Lorrain E. Effets cellulaires et moléculaires de l’hyperforine, un antidépresseur végétal: revue de la littérature. L’Encephale. 2013;40(2):108–113.
26. Trofimiuk E, Holownia A, Braszko JJ. Activation of CREB by St. John’s wort may diminish deletorious effects of aging on spatial memory. Arch Pharm Res. 2010;33(3):469–77.
27. Crupi R, Abusamra YA, Spina E, Calapai G. Preclinical data supporting/refuting the use of Hypericum perforatum in the treatment of depression. CNS Neurol Disord Drug Targets. 2013;12(4):474–86.
28. Kraus B, Wolff H, Elstner EF, Heilmann J. Hyperforin is a modulator of inducible nitric oxide synthase and phagocytosis in microglia and macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):541–53.
29. Bukhari IA, Dar A. Behavioral profile of Hypericum perforatum (St. John’s wort) extract. A comparison with standard antidepressants in animal models of depression. Eur Rev Med Pharmacol Sci. 2013;17(8):1082–9.
30. Liu JX, Fang YQ, Wei ZX, Yang XQ, Zeng LH. Synergic antidepressive effect of quercetin and Hypericum perforatum extract in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42(6):615–9. (Journal of Zhejiang University Medical Sciences).
31. Uzbay IT, Coskun I, Kayir H, Ozturk N, Ozturk Y. Extract of Hypericum perforatum blocks caffeine-induced locomotor activity in mice: a possible role of nitric oxide. Phytother Res. 2007;21(5):415–9.
32. Grundmann O, Kelber O, Butterweck V. Effects of St. John’s wort extract and single constituents on stress-induced hyperthermia in mice. Planta Med. 2006;72(15):1366–71.
33. Crupi R, Mazzon E, Marino A, Spada GL, Bramanti P, Battaglia F, et al. Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement Altern Med. 2011;11:7.
34. Vissiennon C, Nieber K, Kelber O, Butterweck V. Route of administration determines the anxiolytic activity of the flavonols kaempferol, quercetin and myricetin—are they prodrugs? J Nutr Biochem. 2012;23(7):733–40.
35. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung. 2005;55(10):561–8.
36. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung. 2005;55(1):15–22.
37. Trofimiuk E, Holownia A, Braszko JJ. St. John’s wort may relieve negative effects of stress on spatial working memory by changing synaptic plasticity. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(4):415–22.
38. Trofimiuk E, Braszko JJ. Alleviation by Hypericum perforatum of the stress-induced impairment of spatial working memory in rats. Naunyn Schmiedebergs Arch Pharmacol. 2008;376(6):463–71.
39. Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr Top Behav Neurosci. 2011;7:121–47.